Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
42.87
-0.12 (-0.28%)
Official Closing Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
30
31
Next >
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
April 28, 2023
Microsoft, Meta, Cloudflare and Crocs were among the many big movers.
Via
Investor's Business Daily
GSK Stock: A Value Trap or a Hidden Gem?
April 27, 2023
GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. Here's why GSK stock is still a buy.
Via
InvestorPlace
A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US
April 27, 2023
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure...
Via
Benzinga
GSK Clocks 10% Growth In Q1 Sales Excluding COVID-19 Products, Reaffirms Guidance
April 26, 2023
Via
Benzinga
This Favorable Sign Appears On GSK's Chart
April 14, 2023
Via
Benzinga
This House of Representative Just Sold Up To $100K In GSK Stock
April 05, 2023
Via
Benzinga
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?
April 27, 2023
The company reported lighter-than-expected declines due to Keytruda and Gardasil.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
April 26, 2023
Via
Benzinga
3 Biotechs That Might Get Bought Out in 2023
April 26, 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year.
Via
The Motley Fool
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls
April 26, 2023
Both GSK and Roche experienced declining Covid-related sales in the first quarter.
Via
Investor's Business Daily
Was This Acquisition a Savvy Play by This Big Pharma Stock?
April 26, 2023
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health.
Via
The Motley Fool
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
April 25, 2023
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
April 25, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
April 25, 2023
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Via
The Motley Fool
Second Quarter Outlook For Biotech Stocks
April 25, 2023
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.
Via
Talk Markets
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
April 24, 2023
Via
Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
April 21, 2023
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.
Via
Benzinga
Why Shares of Bellus Health Skyrocketed This Week
April 20, 2023
The company has received a buyout offer from GSK.
Via
The Motley Fool
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
April 18, 2023
From
BELLUS Health Inc.
Via
Business Wire
Why BELLUS Health Stock Is Rocketing Higher Today
April 18, 2023
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today.
Via
The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
April 18, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
April 18, 2023
Shares of its takeover candidate nearly doubled on the news.
Via
Investor's Business Daily
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
April 18, 2023
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs
Via
Benzinga
Why Is Bellus Health (BLU) Stock Up 98% Today?
April 18, 2023
Bellus Health (BLU) stock is taking off on Tuesday after the company announced a $2 billion acquisition deal with GSK (GSK).
Via
InvestorPlace
GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition
April 18, 2023
Via
Benzinga
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
April 13, 2023
There's such a big need in preventing RSV that multiple companies should be big winners.
Via
The Motley Fool
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
April 11, 2023
The company bulks up its pipeline by regaining the rights to two of its clinical programs.
Via
The Motley Fool
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
April 11, 2023
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a...
Via
Benzinga
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
April 11, 2023
- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will...
Via
Newsfile
Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging
April 10, 2023
While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.